Get the Stockscreener App
2.94
6.07%
-0.19
After Hours:
2.92
-0.02
-0.68%
Gridai Technologies Corp stock is traded at $2.94, with a volume of 50,634.
It is down -6.07% in the last 24 hours and up +0.00% over the past month.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$3.13
Open:
$3.1
24h Volume:
50,634
Relative Volume:
6.29
Market Cap:
$9.88M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+22.50%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.81
$3.17
1-Week Range:
$2.30
$3.2499
52-Week Range:
$2.0975
$3.2499
Gridai Technologies Corp Stock (GRDX) Company Profile
Name
Gridai Technologies Corp
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare GRDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRDX
Gridai Technologies Corp
|
2.94 | 10.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gridai Technologies Corp Stock (GRDX) Latest News
Entero Regains Nasdaq Compliance With Grid AI Acquisition - Monroe Evening News
GridAI Technologies Corp. Announces Appointment of Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - Black Hills Pioneer
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX" - Lohud
GridAI Technologies Announces Board Changes and Rebranding - The Globe and Mail
GridAI appoints Marshall Chapin as CEO of energy-orchestration subsidiary - Yahoo Finance
GridAI Technologies Corp. Announces Board and Committee Changes - marketscreener.com
GridAI Technologies Corp. Appoints Marshall Chapin as Chief Executive Officer of wholly-owned operating subsidiary GridAI, Inc - marketscreener.com
GridAI Technologies (NASDAQ: GRDX) taps Marshall Chapin to lead AI data-center grid unit - Stock Titan
Entero Therapeutics Stock Gains 5% Ahead Of Name Change To GridAI - Nasdaq
Entero Therapeutics Stock Jumps After Company Rebrands As GridAI Technologies Corp. - MSN
Entero Therapeutics (ENTO) to Rebrand as GridAI (GRDX) Technologies - GuruFocus
Entero Therapeutics to Change Name to GridAI Technologies - marketscreener.com
Entero Therapeutics stock rises ahead of name change to GridAI By Investing.com - Investing.com South Africa
Entero Therapeutics stock rises ahead of name change to GridAI - Investing.com India
Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy - Greenville Online
Entero (NASDAQ: ENTO) Grid AI LOI with First Hyperscaler AI Data-Center Client - Stock Titan
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid - St. Cloud Times
Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid - Record Searchlight
Entero Therapeutics (NASDAQ: ENTO) to name U.S. CEO and Executive Chairman for Grid AI - Stock Titan
Entero Therapeutics (NASDAQ: ENTO) acquires 100% of Grid AI, regains Nasdaq compliance - Stock Titan
$2.5B market opportunity: Entero Therapeutics acquires GRID AI to scale grid orchestration - Stock Titan
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand - Yahoo Finance
Entero Therapeutics Plans 1:3 Reverse Split as Shares Drop Below Nasdaq Minimum - Stock Titan
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules - Stock Titan
Entero Therapeutics, Inc. Chief Financial Officer Changes - marketscreener.com
Entero Therapeutics Appoints Richard Paolone as CEO - marketscreener.com
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - marketscreener.com
Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - marketscreener.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAF, ATSG, ENTO, AVTE on Behalf of Shareholders - marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - marketscreener.com
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform - Stock Titan
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - marketscreener.com
Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings - marketscreener.com
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - marketscreener.com
Entero Therapeutics Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - marketscreener.com
Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - marketscreener.com
ENTOEntero Therapeutics Latest Stock News & Market Updates - Stock Titan
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase - marketscreener.com
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference - marketscreener.com
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico - marketscreener.com
First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders - marketscreener.com
Gridai Technologies Corp Stock (GRDX) Financials Data
There is no financial data for Gridai Technologies Corp (GRDX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):